Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3976504 | Brachytherapy | 2015 | 9 Pages |
Abstract
With high-quality brachytherapy dose distributions, supplemental EBRT did not influence BF or PCSM for patients with intermediate-risk disease. The number of patients with Gleason score 8-9 was too small to determine the role of supplemental EBRT in that cohort.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Gregory S. Merrick, Kent E. Wallner, Robert W. Galbreath, Wayne M. Butler, Ryan Fiano, Peter F. III, Edward Adamovich,